Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.57 |
| ▸ | APP | P05067 | 4/20 | 0.57 |
| ▸ | SNCA | P37840 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.51 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.51 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | RXRA | P19793 | 5/20 | 0.48 |
| ▸ | RARA | P10276 | 5/20 | 0.48 |
| ▸ | RARB | P10826 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8462052 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL8458864 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL19652484 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL8950124 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL19652488 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL8460696 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL8950189 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL9117657 | 0.93 | ALDH1A1 (0.60) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL7694175 | 0.93 | ALDH1A1 (0.60) | ALDH1A1CYP3A4APPSNCAALOX15 | |
| SCHEMBL21959207 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CYP3A4APPSNCAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013700-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2020-04-30 | — | — | US | disclosed |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016085939-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-06-02 | — | — | WO | disclosed |
| EP-0808159-A1 | USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024344-A1 | USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129453-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | ALDH1A1 203/4885CYP3A4 2222/4885APP 2952/4885 |
| US-20170340581-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, ADH1B, ADCYAP1R1 | ALDH1A1 198/4885CYP3A4 2268/4885APP 2903/4885 |
| US-10363231-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | ALDH1A1 198/4885CYP3A4 2268/4885APP 2903/4885 |
| US-11013700-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, ADH1B, ADCYAP1R1 | ALDH1A1 203/4885CYP3A4 2222/4885APP 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.